To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Catamaran Bio gathers $42m
Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing.
